

ANADOLU^H

In Affiliation with
JOHNS HOPKINS MEDICINE



Name : Ilker TINAY, MD, FEBU, FACS

Present Position : Professor of Urology
Division of Urological Oncology

Executive Board Member
Association of Urooncology, Turkey

Secretary of the Bladder Tumors Research Group
Association of Urooncology, Turkey

Medical License Number : 114904

Birth date and place : May 30, 1978, Istanbul, Turkey

E-mail : ilker.tinay@anadolusaglik.org

Twitter : @itinay

LinkedIn : Ilker Tinay

Instagram : ilkertinay

Citizenship : Turkish

Language competence : Turkish, German (Sprachdiplom), English (TOEFL)

PROFESSIONAL SUMMARY:

- ❖ Physician-scientist with in-depth urological oncology experience in both clinical practice and academia

Areas of Expertise:

- Rich experience in academic urological oncology, publishing, teaching and invited speaker experiences
- Urological oncology opinion leader in Turkey
- Urological oncology clinical Phase 3 trial experience
- Deep understanding and experience with liquid biomarkers, namely microRNA in prostate and urothelial carcinoma
- **Minimal invasive and open tumor surgery** with particular expertise;
 - ⇒ in prostate cancer
 - ⇒ in kidney cancer
 - ⇒ urothelial carcinoma of the bladder and upper urinary tract
 - ⇒ retroperitoneal post-chemotherapy resection (RPLND) germ cell tumors

WORK EXPERIENCE:

February 2020-	Anadolu Medical Center Department of Urology/Uro-oncology
October 2017 - 2020	Associate Professor of Urology Marmara University School of Medicine
April 2014 – October 2017	Assistant Professor of Urology Marmara University School of Medicine
November 2011 – April 2014	University Lecturer Marmara University School of Medicine
March 2010 – June 2011	Urologist Kurtalan State Hospital, Siirt, TURKEY
March 2009 – March 2010	Urologist Balikesir Military Hospital, TURKEY

POSTGRADUATE TRAINING/ FELLOWSHIP APPOINTMENTS:

April 2015 – September 2015	Clinical Observer (Robot Assisted Laparoscopic Surgery Urological Oncology) Steven L. Chang Brigham and Women's Hospital Harvard Medical School Boston, MA, USA
October 1, 2014 – September 30, 2015	Urologic Oncology Research Fellow Adam Kibel / Li Jia Research Lab Harvard Medical School Boston, MA, USA
November 2003 – 2008	Residency Training Program in Urology, Department of Urology, Marmara University School of Medicine, Istanbul, Turkey
May 2007	Fellowship in Laparoscopic Urology, Heidelberg University Medical School, SLK Kliniken Heilbronn GmbH, Heilbronn, Germany
August – October 2005	Fellowship in Transplantation Surgery, Department of Surgery, Humboldt University School of Medicine, Berlin, Germany

MEDICAL SCHOOL EDUCATION:

1997-2003	Istanbul Faculty of Medicine, Istanbul University, Turkey
July – August 2000	General Surgery and Colorectal Surgery Clerkship Cleveland Clinic Foundation, Cleveland, U.S.A
July – August 1999	Basic and Clinic Microbiology Clerkship Oslo University Hospital, Ulleval, Norway

CERTIFICATIONS:

November 2008	Board Certified Urology (Turkey, active)
June 2010	Fellow of European Board of Urology (FEBU)
October 2018	Fellow of American College of Surgeons (FACS)

INTERNATIONAL MEMBERSHIPS:

1. Member of the European Association of Urology
2. Member of American Urological Association
3. Member of American College of Surgeons
4. International Bladder Cancer Network

AWARDS:

1. Marmara University School of Medicine

Resident's Science Encouragement Award – 2008

2. Best Young Academician Oral Presentation Award

Annual Congress of the Society of Urological Surgery in Turkey, 2012

3. Association of Urooncology, Turkey - 2019 Scientific Research Award

INTERNATIONAL PEER REVIEWED PUBLICATIONS

1. Kidney loss due to periureteral fibrosis and ureteral obstruction secondary to migration of subureterically injected calcium hydroxylapatite. Önel FF, Tarcan T, **Tinay I**, Kotiloğlu E, Şimşek F. *Journal of Pediatric Urology*, 2006; 2 (5): 503-508
2. Long-term results of endoscopic treatment of vesicoureteral reflux with the sub-ureteric injection of calcium hydroxyapatite. Tarcan T, **Tinay I**, Temiz Y, Şimşek F. *International Urology and Nephrology* 2007; 39(4): 1011-1014
3. A new suture technique for anastomosis in radical retropubic prostatectomy and early removal of urethral catheter. Türkeri L, Temiz Y, Yazıcı CM, **Tinay I**. *The Canadian Journal of Urology* 2007; 14(6): 3697-3701
4. Erectile dysfunction following Radiotherapy and Brachytherapy for prostate cancer. Akbal C, **Tinay I**, Şimşek F, Türkeri L. *International Urology and Nephrology* 2008; 40(2): 355-63
5. Advances in the Understanding of the Early Detection of Bladder Cancer. Türkeri L and **Tinay I**. *European Urological Review* 2008; 3(2): 28-30
6. Outcome of preemptive penile rehabilitation before bilateral cavernosal nerve injury in rats. Tavukcu HH, Akbal C, **Tinay I**, Simsek F, Türkeri L. *World Journal of Urology* 2010; 28(6): 735-40
7. Recent Developments in Research and Treatment of Testicular Cancer: Highlights from Oncologic Congresses in 2009. **Tinay I** and Türkeri L. *European Urology Supplements* 2010; 9(3): 462-466
8. The value of sacral skin lesions in predicting occult spinal dysraphism in children with voiding dysfunction and normal neurological examination. Tarcan T, **Tinay I**, Temiz Y, Alpay H, Ozek M, Simsek F. *J Pediatr Urol*. 2012; 8(1): 55-58
9. Intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model. **Tinay I**, Tanidir Y, Cikler E, Cetinel S, Tarcan T. *Neurourol Urodyn*. 2012; 31(4): 564-70

10. Beneficial effects of quercetin on rat urinary bladder after spinal cord injury. Cevik O, Ersahin M, Sener TE, **Tinay I**, Tarcan T, Cetinel S, Sener A, Toklu HZ and Sener G. *Journal of Surgical Research*, 2013
11. An Alternative for Short Renal Vein during Kidney Transplantation: Long-term Experience with Polyethylene Terephthalate (Dacron) Vascular Graft. **Tinay I**, Temiz Y, Ilker Y, Tuglular S and Turkeri L. *Urology* 2013; 82(1): 245-7
12. Quercetin treatment against ischemia/reperfusion injury in rat corpus cavernosum tissue: role on apoptosis and oxidative stress. Cevik O, Cadirci S, Sener TE, **Tinay I**, Akbal C, Tavukçu HH, Cetinel S, Kiran D, Sener G. *Free Radic Res.* 2013; 47(9): 683-91
13. Diagnostic value of the pediatric lower urinary tract symptom score in children with overactive bladder. Akbal C, Sahan A, Sener TE, Sahin B, **Tinay I**, Tarcan T, Simşek F. *World Journal of Urology* 2014; 32(1): 201-8
14. Melatonin and tadalafil treatment improves erectile dysfunction after spinal cord injury in rats. Tavukçu HH, Sener TE, **Tinay I**, Akbal C, Erşahin M, Cevik O, Cadirci S, Reiter RJ, Sener G. *Clinical and Experimental Pharmacology and Physiology* 2014; 41(4): 309-16
15. High rate of sexual dysfunction following surgery for rectal cancer. Attaallah W, Ertekin C, **Tinay I**, Yegen C. *Annals Coloproctology* 2014; 30(5): 210-5
16. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin. Baltacı S, Bozlu M, Yıldırım A, Gökçe Mİ, **Tinay I**, Aslan G, Can C, Türkeri L, Kuyumcuoğlu U, Mungan A. *BJU Int.* 2015 Nov;116(5):721-6
17. Association of BK Virus Titers With Lymphocyte Count in Renal Transplant Patients. Velioglu A, Aksu B, Ascioglu E, Arıkan H, **Tinay I**, Yardimci S, Yegen C, Tuglular S, Ozener C. *Transplant Proc.* 2015 Jun;47(5):1421-4
18. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. Allard CB, Gelpi-Hammerschmidt F, Harshman LC, Choueiri TK, Faiena I, Modi P, Chung BI, **Tinay I**, Singer EA, Chang SL. *Urol Oncol.* 2015 Nov;33(11):496.e11-6

19. The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. Gelpi-Hammerschmidt F, **Tinay I**, Allard CB, Su LM, Preston MA, Trinh QD, Kibel AS, Wang Y, Chung BI, Chang SL. *J Urol*. 2016 Feb;195(2):399-405
20. Trends in utilization, perioperative outcomes and costs for nephroureterectomies in the management of upper tract urothelial carcinoma (UTUC): a 10-year population-based analysis. **Tinay I**, Gelpi-Hammerschmidt F, Leow JJ, Allard CB, Rodriguez D, Wang Y, Chung BI, Chang SL. *BJU International* (2015), Doi: 10.1111/bju
21. Antioxidant Agent Quercetin Prevents Impairment of Bladder Tissue Contractility and Apoptosis in a Rat Model of Ischemia/Reperfusion Injury. **TINAY I**, SENER TE, ÇEVİK Ö, CADIRCI S, TOKLU H, ÇETINEL S, SENER G, TARCAN T. *LUTS: Lower Urinary Tract Symptoms* (2015), Doi: 10.1111/luts.12125
22. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration resistant prostate cancer. Zheng D, Gui B, Gray KP, **Tinay I**, Rafiei S, Huang Q, Sweeney CJ, Kibel AS, Jia L. *Oncogene* (2016), Doi: 10.1038/onc.2016.13
23. Is 40?cm?H2O detrusor leak point pressure cut-off reliable for upper urinary tract protection in children with myelodysplasia? Tarcan T, Sekerci ÇA, Akbal C, **Tinay I**, Tanidir Y, Sahan A, Sahin B, Top T, Simsek F. *Neurourology and Urodynamics* (2016), Doi: 10.1002/nau.23017
24. Differentiation of ureteral stones and phleboliths using Hounsfield units on computerized tomography: a new method without observer bias. Tanidir Y, Sahan A, Asutay MK, Sener TE, Talibzade F, Garayev A, Tinay I, Sekerci CA, Simsek F. *Urolithiasis*. 2017 Jun;45(3):323-328
25. The effect of doxazosin and sildenafil citrate combination on bladder tissue contractility, alpha adrenergic receptor, and iNOS subtype expression in a male rat model of partially bladder outlet obstruction. Gumrah A, Tanidir Y, Tinay I, Ozyurek M, Tarcan T. *Neurourol Urodyn*. 2017 Aug;36(6):1479-1487

26. The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. Top T, Sekerci CA, Isbilen-Basok B, Tanidir Y, Tinay I, Isman FK, Akbal C, Simsek F, Tarcan T. *Neurourol Urodyn*. 2017 Sep;36(7):1896-1902
27. Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. Jia L, Gui B, Zheng D, Decker KF, Tinay I, Tan M, Wang X, Kibel AS. *Prostate*. 2017 Jun;77(9):1000-1011.
28. Full blown nephrotic syndrome due to unilateral obstruction of the uretero-pelvic junction. Atas DB, Arikan H, Tinay I, Ascioglu E, Velioglu A, Koc M, Tuglular S, Ozener C. *Nephrology (Carlton)*. 2017 Jun;22(6):498
29. Clinical Case Discussion: Bilateral Synchronous Testicular Cancer and Organ-sparing Surgery. Sener TE, Ozveren B, Tinay I, Cam K, Turkeri L. *Eur Urol Focus*. 2016 Aug 23. pii: S2405-4569(16)30111-0. doi: 10.1016/j.euf.2016.08.003
30. Jia L, Gui B, Zheng D, Decker KF, Tinay I, Tan M, Wang X, Kibel AS. Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. *Prostate*. 2017 Jun;77(9):1000-1011. doi: 10.1002/pros.23356
31. Sener TE, Ozveren B, Tinay I, Cam K, Turkeri L. Clinical Case Discussion: Bilateral Synchronous Testicular Cancer and Organ-sparing Surgery. *Eur Urol Focus*. 2016 Aug 23. pii:S2405-4569(16)30111-0. doi:10.1016/j.euf.2016.08.003
32. Tinay I, Aslan G, Kural AR, Özen H, Akdoğan B, Yıldırım A, Ongün Ş, Özkan A, Esen T, Zorlu F, Dillioğlugil Ö, Bekiroglu N, Türkeri L; Members of Urooncology Association. Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort. *Urol Int*. 2018;100(1):43-49. doi: 10.1159/000481266

33. Tinay I, Tan M, Gui B, Werner L, Kibel AS, Jia L. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. *Prostate*. 2018 Sep;78(12):927-937. doi: 10.1002/pros.23650
34. Sener TE, Tavukcu HH, Atasoy BM, Cevik O, Kaya OT, Cetinel S, Dagli Degerli A, Tinay I, Simsek F, Akbal C, Buttice S, Sener G. Resveratrol treatment may preserve the erectile function after radiotherapy by restoring antioxidant defence mechanisms, SIRT1 and NOS protein expressions. *Int J Impot Res*. 2018 Aug;30(4):179-188. doi: 10.1038/s41443-018-0042-6
35. Amuran GG, Eyuboglu IP, Tinay I, Akkiprik M. New Insights in Bladder Cancer Diagnosis: Urinary miRNAs and Proteins. *Med Sci (Basel)*. 2018 Dec 7;6(4). pii: E113. doi: 10.3390/medsci6040113. Review. PubMed PMID: 30544619; PubMed Central PMCID: PMC6318758.
36. Guran T, Yesil G, Turan S, Atay Z, Bozkurtlar E, Aghayev A, Gul S, Tinay I, Aru B, Arslan S, Koroglu MK, Ercan F, Demirel GY, Eren FS, Karademir B, Bereket A. PPP2R3C gene variants cause syndromic 46,XY gonadal dysgenesis and impaired spermatogenesis in humans. *Eur J Endocrinol*. 2019 May 1;180(5):291-309. doi: 10.1530/EJE-19-0067. PubMed PMID: 30893644.
37. Baykan O, Akgul M, Uren N, Yaman A, Tinay I, Ergul E, Sazci A, Turkeri L, Haklar G. The Relationship Between Urothelial Type Bladder Cancer, Plasma 25-Hydroxyvitamin D Levels, and Vitamin D Receptor Apal BsmI FokI, and TaqI Polymorphisms. *Clin Lab*. 2019 Apr 1;65(4). doi: 10.7754/Clin.Lab.2018.180339. PubMed PMID: 30969078.
38. Mehdiyev S, Velioglu A, Arikan H, Asicioglu E, Cincin A, Demirbas T, Tinay I, Ozener C, Tuglular S. Cardiac Risk Assessment in Kidney Transplant Candidates: Clinical Usefulness of Different Guidelines. *Transplant Proc*. 2019 May;51(4):1058-1063. doi: 10.1016/j.transproceed.2019.01.101. Epub 2019 Feb 8. PubMed PMID: 31101171.

39. Kanar BG, Ozben B, Sunbul M, Şener E, Ozkan O, Tinay I, Tigen MK. Androgen-deprivation therapy impairs left ventricle functions in prostate cancer patients. *Int Urol Nephrol*. 2019 Jul;51(7):1107-1112. doi: 10.1007/s11255-019-02184-4. Epub 2019 Jun 4. PubMed PMID: 31165396.
40. Inanir S, Kesim S, Ergelen R, Tinay İ, Türköz HK. 68Ga-PSMA PET/CT in Giant Retroperitoneal Liposarcoma. *Clin Nucl Med*. 2019 Nov;44(11):e612-e613. doi: 10.1097/RLU.0000000000002762. PubMed PMID: 31524684.
41. Güllü Amuran G, Tinay I, Filinte D, Ilgin C, Peker Eyüboğlu I, Akkiprik M. Urinary micro-RNA expressions and protein concentrations may differentiate bladder cancer patients from healthy controls. *Int Urol Nephrol*. 2019 Nov 2. doi: 10.1007/s11255-019-02328-6. [Epub ahead of print] PubMed PMID: 31679136.
42. Nazım C Demircan¹, Özkan Alan¹, Tuğba Başoğlu Tüylü¹, Tuğba Akın Telli¹, Rukiye Arıkan¹, Furkan C Çiçek², Özlem Ercelep¹, Mehmet A Öztürk³, İlknur Alsan Çetin⁴, Rabia Ergelen⁵, İlker Tinay⁶, Nalan Akgül Babacan¹, Serap Kaya¹, Faysal Dane¹, Perran F Yumuk¹. Impact of the Charlson Comorbidity Index on Dose-Limiting Toxicity and Survival in Locally Advanced and Metastatic Renal Cell Carcinoma Patients Treated With First-Line Sunitinib or Pazopanib [published online ahead of print, 2019 Dec 2]. *J Oncol Pharm Pract*. 2019;1078155219890032. doi:10.1177/1078155219890032
43. The Early Impact of COVID-19 Pandemic on Surgical Urologic Oncology Practice in Turkey: Multi-Institutional Experience From Different Geographic Areas. **Tinay I**, Ozden E, Suer E, Bozkurt O, Izol V, Sahin B, Turkeri L. *Urology*. 2020 Aug;142:29-31
44. Hyperbaric oxygen therapy prevents subarachnoid hemorrhage-induced apoptosis and impaired contractility of the rabbit bladder. **Tinay I**, Celik O, Sekerci CA, Cadirci S, Cevik O, Oroglu B, Sener G, Tarcan T. *Neurourol Urodyn*. 2020 Jun;39(5):1276-1282
44. Re: Marc-Oliver Grimm, Antione G. van der Heijden, Marc Colombel, et al. Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation

Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. In press.
<https://doi.org/10.1016/j.eururo.2020.04.066>.
Karabay E, **Tinay İ**. Eur Urol. 2020 Oct;78(4):e161-e162

45. The impact of tumor invasion to muscularis mucosaevascular plexus on patient outcome in pT1 bladder urothelial carcinoma.
Sahan A, Gerin F, Garayev A, Bozkurtlar E, Çubuk A, Ozkaptan O, Ertas K, Tanıdır Y, Cam HK, **Tinay İ**. Arch Ital Urol Androl. 2020 Oct 2;92(3)
46. The Effect of Diagnostic Ureterorenoscopy on Intravesical Recurrence in Patients Undergoing Nephroureterectomy for Primary Upper Tract Urinary Carcinoma.
İzol V, Deger M, Ozden E, Bolat D, Argun B, Baltaci S, Celik O, Akgul HM, **Tinay İ**, Bayazit Y; Bladder Cancer Study Group of Association of Urooncology, Turkey. Urol Int. 2020 Dec 2:1-7
47. Ta grade 3/high grade non-invasive bladder cancer: Should we perform a second TUR?
Tinay İ, Baltaci S, Demirdag C, Akdogan B, Yucetas U, Simsekoglu MF, Haberal HB, Bozlu M, Izol V, Aslan G, Bekiroğlu N; Bladder Cancer Study Group of Urooncology Association, Turkey. *Int J Clin Pract.* 2020 Dec 10:e13924